Leuven, Belgium - ThromboGenics NV (Euronext Brussels: THR) announced today that it will give a presentation at the European Society of Ophthalmology Congress, which is held from June 10-13 in Barcelona, Spain.

The presentation 'The industry pipeline for diabetic macular edema (DME), what does it hold?' will be given by Jean Feyen, PhD, Head of R&D at ThromboGenics. In his presentation, Dr Feyen will provide an overview of the current standard of care for DME, the unmet medical need, future treatments for DME currently under development and delivery mechanisms.

ThromboGenics has a pipeline of disease modifying drug candidates targeting the key segments of the diabetic eye disease market: non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, with or without DME.

Dr Feyen's presentation will take place from 11:00 - 11:15am CET, Tuesday 13 June.

'We are honored with this opportunity to join this prestigious meeting of the European Society of Ophthalmology', said Dr. Patrik De Haes, MD, CEO of ThromboGenics NV. 'There is a clear unmet medical need for improved treatment options for diabetic eye disease in general, and diabetic macular edema specifically. Our current development pipeline is focused on addressing this need and we are currently developing 4 new disease modifying therapies, each with the potential to improve on the current standard of care for a number of diabetic eye disease indications.'

ThromboGenics NV published this content on 08 June 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 08 June 2017 05:33:17 UTC.

Original documenthttp://www.thrombogenics.com/content/thrombogenics-present-industry-pipeline-dme-treatments-upcoming-european-society

Public permalinkhttp://www.publicnow.com/view/11B391F95828B84B4C517C6FE587E7D8042CD659